NEW KEYTRUDA (pembrolizumab) Clinical Trial

Discussion Board Forums Clinical Trials NEW KEYTRUDA (pembrolizumab) Clinical Trial

Viewing 10 posts - 1 through 10 (of 10 total)
  • Author
    Posts
  • #91934
    marions
    Moderator

    You are welcome, dear Ali.

    Hugs
    Marion

    #91933
    alikemal
    Spectator

    thanks a lot marions

    #91932
    marions
    Moderator

    Alikemal….I can’t answer the question about cost. You may have to reach out to Merck
    https://www.merckaccessprogram-keytruda.com/

    For success you may want to peruse Matt’s postings:

    CtWong: http://www.cholangiocarcinoma.org/punbb/viewtopic.php?id=12512

    Matt: http://www.cholangiocarcinoma.org/punbb/search.php?action=show_user_posts&user_id=10126

    Hugs
    Marion

    #91931
    alikemal
    Spectator

    how much does 1 cycle Keytruda cost in US ?

    Can Keytruda cure Cholangiocarcinoma ?

    #91930
    marions
    Moderator

    The UCSF trial closed quickly with 10 patients filling the 100 worldwide slots designated to cholangiocarcinoma patients.
    OPDIVO® (nivolumab) and KEYTRUDA® (pembrolizumab) are identical and both can be prescribed off-label (believe cost to patient is approx. 17 thousand Dollars), or through the physician initiated expanded access program .

    Expanded Access (Compassionate Use)
    Keytruda, Merck : http://www.merck.com/about/eap_faq.html

    OPDIVO – Bristol-Mayers-Scibb
    http://www.bms.com/clinical_trials/investigator_sponsored_research/Pages/expanded-access-program.aspx

    Hugs
    Marion

    #91929
    katrina
    Spectator

    Thank you so much for letting us know. I have kept one eye on Keytruda for many months. I was discouraged when I heard that the FDA cleared it only for a few types of cancer, but it opened the gate of promise for Trials. It sure would make all the headlines if it works well for many. I also wonder how long Keytruda has been in any trials in other countries?

    Two people said they heard that it was only tested on people with a certain gene alteration. I hope and pray that isn’t true.

    #91928
    ctwong81
    Spectator

    @middlesister1 – Mom’s still doing great. :) Thanks for your kind words!

    @lainy
    – Of course! We want to continue to spread awareness and hope! Take care! :)

    #91927
    lainy
    Spectator

    Hi Colleen, thank you for the great report on Keytruda! I have read so many good things and am hoping this gives us a turn in the road. Also hoping your Mom is doing well. I know a ton of members are going to really appreciate your post! Take care.

    #91926
    middlesister1
    Moderator

    Thanks for sharing- I hope your Mom is still doing well!

    #12289
    ctwong81
    Spectator

    Hi All:
    I just received details on a NEW clinical trial for KEYTRUDA. This is an international trial, targeting approx. 50 patients at UCSF.

    For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT02628067?term=keynote+158&rank=

    Or contact:
    Wesley Goodman-Levy
    Clinical Research Coordinator
    Early Phase Investigational Therapeutics UCSF Helen Diller Family
    Comprehensive Cancer Center
    1600 Divisadero Street, Room B728K
    Mailbox 1297
    San Francisco, CA 94115
    Tel: 415-514-6363
    Fax: 415-514-6955

    The purpose of this study is to look at the effects, good or bad, of
    pembrolizumab (MK-3475, also known as KEYTRUDA) on you and your
    advanced solid tumors, to test the safety and tolerability of the
    research study drug, pembrolizumab (MK-3475), and to see if
    pembrolizumab

    (MK-3475) has anti-tumor activity in advanced solid tumors in patients
    who have received prior treatment. Pembrolizumab is an investigational
    drug, which has been approved for use in certain types of adult
    melanoma. However the Food and Drug Administration (FDA) has not
    approved pembrolizumab in any other cancers (including
    advanced/unresectable or metastatic solid tumors). Your immune system
    is designed to help your body fight off sickness. Some cancers are able to prevent the immune system from destroying the cancer cells. Pembrolizumab is a protein that is designed to block these effects and allow your body’s immune system to destroy the cancer cells.

    If you become part of this study you will take pembrolizumab every 3 weeks at a dose of 200 mg.
    Pembrolizumab is administered as a 30 minute intravenous (IV) infusion
    (though a needle in a vein your arm or other part of your body) on Day
    1 of each treatment cycle. The time between doses of pembrolizumab
    will be every 3 weeks. Your treatment may be withheld if you experience serious side effects.

Viewing 10 posts - 1 through 10 (of 10 total)
  • The forum ‘Clinical Trials’ is closed to new topics and replies.